

## **Product datasheet for TL302252**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## PRRT2 Human shRNA Plasmid Kit (Locus ID 112476)

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** PRRT2 Human shRNA Plasmid Kit (Locus ID 112476)

**Locus ID:** 112476

Synonyms: BFIC2; BFIS2; DSPB3; DYT10; EKD1; FICCA; ICCA; IFITMD1; PKC

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

**Mammalian Cell** 

Puromycin

Selection:

Format: Lentiviral plasmids

**Components:** PRRT2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 112476).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

**RefSeq:** NM 001256442, NM 001256443, NM 145239, NM 145239.1, NM 145239.2, NM 001256443.1,

NM 001256442.1, BC011405, BC053594

UniProt ID: Q7Z6L0

Summary: This gene encodes a transmembrane protein containing a proline-rich domain in its N-

terminal half. Studies in mice suggest that it is predominantly expressed in brain and spinal cord in embryonic and postnatal stages. Mutations in this gene are associated with episodic kinesigenic dyskinesia-1. Alternatively spliced transcript variants encoding different isoforms

have been found for this gene. [provided by RefSeq, Jan 2012]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).